Pathological diagnosis of gastrointestinal stromal tumors (GISTs) is based on histological findings and immunohistochemical demonstration of the KIT protein. KIT-negative GISTs account for B5% of cases and cause diagnostic difficulties. In the era of imatinib therapy, a correct diagnosis of GISTs is important for therapeutic reasons regardless of KIT expression. Recently, DOG1 has been introduced as an important diagnostic marker with high sensitivity and specificity. In this study, immunohistochemical staining for DOG1 and protein kinase C-h (PKC-h) in whole tissue sections, and mutation analyses for KIT and PDGFRA were performed in 26 KIT-negative GISTs. Tissue microarrays of 112 KIT-positive GISTs were used as controls. Overall, 25 KIT-negative GISTs were located in the stomach, and 1 in the rectum. The histological subtype was spindle in 12, epithelioid in 11, and mixed in 3 cases. The expression of DOG1 and PKC-h was positive in 24 (92%) and in 25 cases (96%), respectively. All 26 KIT-negative GISTs expressed either DOG1 or PKC-h, and 23 cases (89%) were positive for both makers. PKC-h was positive in two cases (8%), which lacked both KIT and DOG1 expressions. Mutation analysis showed PDGFRA exon 18 mutation in 15 cases (58%) and KIT exon 11 mutation in 1 case (4%), whereas the remaining 10 cases (39%) were wild type for both KIT and PDGFRA. The expression of DOG1 and PKC-h showed no significant difference in KIT-negative and KIT-positive GISTs (P ¼ 1.000 and P ¼ 0.167, respectively). Our findings suggest that both DOG1 and PKC-h can be used in the diagnosis of KIT-negative GISTs and they show positive staining even in KIT-negative tumors, which are wild type for KIT and PDGFRA on mutation analysis.
KIT (CD117), an immunohistochemical marker constantly expressed in normal interstitial cells of Cajal, is demonstrable in the vast majority of gastrointestinal stromal tumors (GISTs). However, approximately 4-5% of GISTs lack KIT expression despite typical clinicopathological features. [1] [2] [3] These tumors have a predilection for the stomach or omentum, and are commonly of the epithelioid or mixed histological type. [3] [4] [5] The lack of KIT expression is usually found in GISTs that are wild type for KIT and PDGFRA, but is also reported in tumors harboring mutations in exons 9 and 11 of KIT. 3, 6 In rare cases, they cease to express the KIT protein because of clonal evolution after imatinib therapy. 7, 8 Therefore, it is important to find markers that reliably stain GISTs, which are weak or negative for the KIT protein.
Most GISTs contain oncogenic gain-of-function receptor tyrosine kinase mutations involving KIT (B85%) or PDGFRA (B5%). 9, 10 Inhibition of constitutively activated tyrosine kinases confers clinical responsiveness in advanced GISTs. 11 In addition, the type of mutation in hot-spot regions of KIT or PDGFRA has relevance to prognosis and the likelihood of responsiveness to tyrosine kinase inhibitors. 10, 12 With growing effectiveness and availability of targeted therapies in GISTs, a precise diagnosis is imperative. 13, 14 DOG1 was found to be selectively expressed in GISTs using gene expression profiling studies, although it is not related to oncogenic activation of KIT and PDGRFA. 15 It is a protein encoded by TMEM16A (synonyms include TMEM16, FLJ10261, ANO1, ORAOV2, and TAOS2), which is located within the CCND1-EMS1 locus on the human chromosome 11q13. 16 On the basis of gene expression profile using cDNA microarrays, TMEM16A was found to be upregulated in both KIT and PDGFRA mutant GISTs. 15 Recently, the mouse monoclonal antibody DOG1.1 was introduced as a sensitive diagnostic marker for GISTs with the additional benefit of detecting about one-third of KIT-negative GISTs. 8 It was found to be highly expressed in KIT mutant GISTs and in unusual subtypes lacking KIT or PDGFRA mutations. 8 Moreover, nearly half of KIT-negative GISTs were positive for a new DOG1 antibody (clone K9) on multi-tumor paraffin blocks. 5 Although DOG1 stains about onethird to half of KIT-negative GISTs, the remaining tumors with typical morphological features of GISTs are difficult to validate immunohistochemically. 5, 8 Depending on the DOG1 antibody used, staining in the normal gastric epithelium, carcinomas, germ cell tumors, melanomas, and rarely in some mesenchymal tumors has also been reported. 5, 17 Protein kinase C-y (PKC-y), a member of the PKC family, is expressed in virtually all GISTs and is shown to be very specific by western blots. 18 Several studies have been reported on the utility of PKC-y in identifying KIT-negative GISTs and in discriminating this subset of GISTs from other soft tissue tumors. [18] [19] [20] [21] However, high background staining and expression in schwannomas have limited its diagnostic utility. 2 In our experience, an optimal setting of the staining conditions can remove these problems and yield greater sensitivity and specificity in the diagnosis of KIT-negative GISTs. 19 In this study, the clinicopathological and molecular features of 26 KIT-negative GISTs were analyzed. Immunostaining of DOG1 and PKC-y and mutational analysis for KIT and PDGFRA genes in KIT-negative GISTs were performed, and compared with KIT-positive GISTs.
Materials and methods
Cases consisted of 26 primary tumors having typical clinical and histological features of GISTs, but lacked KIT expression in formalin-fixed paraffinembedded tissues. Typical histological features of spindle cell-type GISTs were relatively uniform eosinophilic cells arranged in short fascicles or whorls with a pale eosinophilic cytoplasm, often with a fibrillary, syncytial appearance. GISTs of the A total of 21 cases had undergone surgical resection at a single institute between 1999 and 2009 out of 754 GISTs (3%), and 5 were from the consultation files of one of the authors (K-M Kim). Four of these KIT-negative tumors were reported in a previous study. 19 Small biopsy specimens and tumors obtained after treatment with imatinib were excluded from this study. Pathological reports and hematoxylin and eosin-stained slides were reviewed in all cases, and estimated tumor characteristics included location, size, histological subtype, and mitotic count per 50 high power fields.
Sections of 4-mm thickness were cut from paraffin blocks, followed by deparaffinization and rehydration. Immunohistochemistry was performed for KIT (polyclonal A4502, Dako, 1:250) in all cases without antigen retrieval, as described previously.
22 DOG1 (clone K9, Leica Microsystems, Wetzlar, Germany, 1:200) was applied after heat-induced antigen retrieval in EDTA buffer at pH 8.0 for 1 h. 5 PKC-y (clone 27, BD Transduction Laboratories, 1:200) and CD34 (clone QBEnd10, Dako, 1:100) immunostaining were also performed using the Leica Bond-Max System after antigen retrieval with Bond Epitope Retrieval Solution (Leica Microsystems). Diaminobenzidine was used as a chromogen. As control, 112 KIT-positive GISTs were used, and two 3-mm-sized cores were taken from representative areas for tissue microarray construction (Isu Abxis Co. Ltd, Seoul, Korea). Slides were scanned using ScanScope CS (Aperio Technologies, Vista, CA), and immunoreactivities were assessed by two pathologists (K-M Kim and G-H Kang) blinded to clinicopathological findings. The staining intensity of DOG1 and PKC-y was graded as negative, weak, moderate, or strong. Cases were considered negative when o10% tumor cells were stained. We considered cases to be positive only when 410% tumor cells showed unequivocal immunoreactivity.
For comparison, 83 additional gastrointestinal mesenchymal tumors that often enter the differential diagnosis of KIT-negative GISTs, including mesenteric fibromatosis (47), schwannoma (6), leiomyoma (6), leiomyosarcoma (6), inflammatory Diagnosis of KIT-negative GISTs fibroid polyp (6), malignant peripheral nerve sheath tumor (6) , and melanoma (6), were also stained for DOG1 and PKC-y.
All 26 KIT-negative and 74 KIT-positive GISTs were analyzed for mutations in exons 9, 11, 13, and 17 of KIT and in exons 12, 14, and 18 of the PDGRFA gene. DNA was extracted from 0.1% methylene bluestained 10-mm-thick sections under microscopy using a 20-G needle and proteinase K solution. PCR products were electrophoresed through 8% polyacrylamide gel with ethidium bromide to confirm correct amplification. The amplified products were purified, and both strands were directly sequenced using the BigDye Terminator v3.1 cycle sequencing kit, followed by analysis using an Applied Biosystems 3700 automated sequencer (Applied Biosystems, Foster City, CA).
Statistical analyses were carried out using SPSS 15.0 for Windows (SPSS Inc., Chicago, IL). Pearson's y test or Fisher's exact test was used to examine the association between categorical variables, and McNemar's test was performed to assess the difference between paired proportions. A P-value o0.05 was considered statistically significant.
Results

Clinical and Pathological Features of KIT-Negative GISTs
The clinicopathological features of 26 KIT-negative GISTs are described in Table 1 . There were 15 men and 11 women with ages ranging from 29 to 75 years (mean, 55.6). All tumors exhibited typical histological features of GISTs with complete loss of KIT expression by immunohistochemistry (Figures 1  and 2 ). All except one KIT-negative GIST were located in the stomach (96%), and the remaining one in the rectum (4%). The histological subtype was spindle in 12 (46%), epithelioid in 11 (42%), and mixed in 3 cases (12%). The histological subclassification of spindle cell GISTs included seven hypercellular, three sclerosing, and two palisading and vacuolated types. Of epithelioid tumors, seven were hypercellular, two sclerosing, and two of the sarcomatous type. 4 On the basis of tumor locations, sizes, and mitotic counts, 9 GISTs (35%) were classified as high, 2 (8%) as moderate, 4 (15%) as low, and 11 (42%) as being at a very low risk of aggressive behavior. 
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Follow-up was available in 25 patients and local recurrence or metastasis was observed in 3 cases, initially classified as being at a high risk of aggressive behavior. Two patients had shown tumor progression before the imatinib era and died of disease. The remaining one patient had a partial response to imatinib during 5 years of follow-up.
Immunohistochemistry and Mutation Analysis in 26 KIT-Negative GISTs
Of 26 KIT-negative GISTs (92%), 24 showed diffuse cytoplasmic and membranous staining for DOG1. The overall cytoplasmic and membranous staining intensity was strong in 12 (46%), moderate in 9 (35%), and weak in 3 cases (12%) (Figure 3) . Diffuse cytoplasmic positivity for PKC-y was observed in 25 cases (96%). The staining intensity was strong in 19 (73%) and weak in the remaining 6 cases (23%) (Figure 4 ). PKC-y was diffusely positive in two GISTs (8%) negative for both KIT and DOG1, but the staining intensity was weak in one of these cases. CD34 was positive in 20 KIT-negative GISTs (77%). In two GISTs negative for both KIT and DOG1, one was focally positive for CD34 and the other was completely negative (Table 2) .
In mesenchymal tumors other than GISTs, all mesenteric fibromatoses, inflammatory fibroid polyps, schwannomas, leiomyomas, malignant peripheral nerve sheath tumors, leiomyosarcomas, and melanomas were negative for DOG1. Two of six schwannomas (33%) and malignant peripheral nerve sheath tumors (33%) were focally positive for PKC-y. However, all mesenteric fibromatoses, inflammatory fibroid polyps, leiomyomas, leiomyosarcomas, and melanomas were completely negative for PKC-y.
On mutation analyses, 15 of 26 cases (58%) harbored mutations in exon 18 of the PDGFRA gene, including 11 missense and 4 deletion mutations. One case (4%) showed deletion mutation in exon 11 of the KIT gene. The remaining 10 GISTs (38%) were wild type for KIT and PDGFRA genes ( Table 2 ). Of the 10 tumors wild type on mutation analysis, DOG1 immunoreactivity was strong in 6, moderate and weak in 1 each, and completely negative in 2 cases. In these two DOG1-negative GISTs, PKC-y was stained diffusely on whole tissue section with strong and weak intensities, respectively. 
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Immunohistochemistry and Mutation Analysis in 112 KIT-Positive GISTs DOG1 was positive in 100 of 112 KIT-positive GISTs (89%). The overall staining intensity was strong in 40 (36%), moderate in 36 (32%), and weak in 24 cases (21%). A total of 93 (83%) KIT-positive GISTs were positive for PKC-y, and the intensity was strong in 71 cases (63%). CD34 was positive in 76 of 112 cases (68%). Of 74 KIT-positive GISTs with mutation results, 52 (70%) revealed KIT exon 11 mutations, including 30 deletion, 6 duplication, and 16 missense mutations. Overall, 10 cases (14%) harbored KIT exon 9 mutations and 3 (4%) had PDGFRA exon 18 mutations.
Comparison Between KIT-Negative and KIT-Positive GISTs
The clinicopathological features and immunohistochemical results of GISTs according to KIT expression are shown in Table 3 . Among 26 KIT-negative and 74 KIT-positive tumors with mutation analyses, KIT mutations were detected in 17 of 39 GISTs (44%) showing pure or mixed epithelioid morphology and in 46 of 61 tumors (75%) with pure spindle cell type, the difference being statistically significant (P ¼ 0.001).
Most KIT-negative GISTs occurred in the stomach compared with KIT-positive tumors (Fisher's exact test, Po0.001), and were more likely to have an epithelioid morphology (P ¼ 0.006). Wild-type KIT and PDGFRA gene status was significantly more common in KIT-negative GISTs than in KIT-positive tumors (P ¼ 0.003). The concordance rate between DOG1 and PKC-y expression was 89 and 83% in KIT-negative and KIT-positive GISTs, respectively. There was no significant difference between the expression of two markers in the KIT-negative and KIT-positive groups (McNemar's test, P ¼ 1.00 and P ¼ 0.16, respectively). The relationship of DOG1 and PKC-y expression is described in Table 4 . KITnegative GISTs were positive for either DOG1 or PKC-y, and six KIT-positive tumors (5%) were negative for both markers. 
Discussion
In this study, we present a series of 26 KIT-negative GISTs in which DOG1 and PKC-y were proven extremely valuable for making a definitive diagnosis. As reported previously, KIT-negative GISTs were more likely to have epithelioid morphology and were commonly located in the stomach. [3] [4] [5] In concordance with previous studies, 24, 25 epithelioid cell morphology was commonly observed in GISTs lacking KIT mutations. KIT-negative and KIT-positive GISTs shared the common clinicopathological features, including patients' age, gender, and the risk of aggressive behavior.
We confirmed that the DOG1 antibody, clone K9, works well on paraffin-embedded tissues and is highly expressed in GISTs irrespective of KIT expression. DOG1 was also positive in 89% of KIT and PDGFRA wild-type GISTs, and the expression was not related to mutational status. As described previously, cytoplasmic staining was more pronounced in spindle cells, whereas epithelioid cells showed prominent membranous staining. 8 It has been demonstrated that clone K9 and monoclonal DOG1.1 are expressed in 95 and 87% of GISTs, respectively, indicating that the new clone K9 antibody may be more sensitive. 5, 17 The positivity of DOG1 in KIT-negative GISTs was variable according to the antibodies used: with DOG1.1, the positivity is 36% 8 and with K9, the positivity is 50-76%. 5, 26 In our study, with clone K9 and whole paraffin tissue blocks, 92% of KIT-negative GISTs were positive for DOG1. This difference may be caused by the type of tissue sections used for immunohistochemistry. We used whole paraffin tissue block instead of multi-tumor blocks containing 5-60 tumors 5 or tissue microarrays. 27 These limit the amount of tumor tissues analyzed for immunoreactivity and does not reflect that daily routine practice in which whole tissue blocks are used for immunohistochemical workup. Miettinen et al 5 also reported that DOG1 (clone K9) reacted slightly better in gastric epithelioid GISTs than in KIT, and that KIT was slightly more sensitive than DOG1 in intestinal GISTs. 5 In our analyses, the positivity for KIT was higher in GISTs of non-gastric locations, and the expression was more frequently observed in spindle cell-type GISTs. However, DOG1 immunoreactivity was not significantly associated with tumor location and histological subtype.
Some authors have noted that PKC-y is not a useful diagnostic marker for GISTs because of high background staining and limited reproducibility. 2, 5, 8, 21 However, we could get a satisfactory signal-to-noise ratio at a dilution of 1:200 with antigen retrieval (PKC-y, clone 27). PKC-y is also reported to be expressed in schwannoma, malignant peripheral nerve sheath tumor, and Ewing's sarcoma/primitive neuroectodermal tumor. 19, 28 In our series, all cases of mesenteric fibromatosis, PDGFRA, platelet-derived growth factor receptor-a; NR, not reported.
Diagnosis of KIT-negative GISTs inflammatory fibroid polyp, leiomyoma, leiomyosarcoma, and melanoma, which mimic GIST and are the usual considerations in differential diagnosis, were completely negative for PKC-y. 19, 21 In previous studies with KIT-negative GISTs, 3-4% was negative for the new DOG1 antibody. 5, 27 PKC-y was positive in two cases (8%) and completely negative for both KIT and DOG1 in this study, which was helpful in validating these cases as GISTs.
In this study, both DOG1 and PKC-y were expressed more frequently in KIT-negative GISTs than in KIT-positive GISTs, but this difference was not statistically significant. These findings are consistent with previous observations that DOG1 shows higher prevalence of positivity in gastric epithelioid GISTs, which are often KIT negative. 5 PKC-y positivity in KIT-negative GISTs has also been reported previously. 19, 20 We also found that 58% of KIT-negative GISTs in our series harbored mutations in exon 18 of PDGFRA, leading to a substitution of valine for aspartic acid (D842V), known to be imatinib mesylate (Gleevec) resistant. 10, 29 The KIT mutation was present in one KIT-negative tumor (4%). In previous studies on KIT-negative GISTs, the PDGFRA mutation (D842V) and the KIT mutation were observed in 30-40% and 0-16% of cases, respectively. 9, 20 Mutations found in 15% of KIT-negative GISTs were PDGFRA exon 18 deletions, which are imatinib sensitive.
1 PDGFRA exon 18 deletion mutations have been reported in 7-17% of KIT-negative tumors, and our results are consistent with previous reports. 3, 8, 30 Wild-type KIT and PDGFRA status was observed in 38% of cases. Medeiros et al 3 and Lee et al 21 reported that 16-70% of KIT-negative tumors were wild type. One of our patients (case 11) was a 29-year-old woman with an epithelioid gastric GIST, which raised the possibility of familial or idiopathic multi-tumor syndrome. 31 However, the presence of a solitary tumor in the absence of a family history, negative chest roentgenogram, and the absence of any adrenal mass ruled out the possibility of Carney triad.
Recently, it has been shown that a subset of GISTs without KIT or PDGFRA mutations are also responsive to imatinib. 2 Although the PDGFRA D842V mutation is intrinsically imatinib resistant, more than two-thirds of KIT-negative tumors are potentially imatinib sensitive. 3, 10, 32 Moreover, imatinib is still regarded as the first-line therapy for advanced GISTs, including those with PDGFRA D842V mutations. 1 In our 26 KIT-negative GISTs, 3 patients showed recurrence of disease and 1 patient with KIT mutation had a partial response to imatinib therapy. Therefore, it is important for pathologists and oncologists to be aware that, in the context of an otherwise typical morphology, a diagnosis of GIST should not be precluded on the basis of negative staining for KIT and such patients should not, a priori, be denied imatinib therapy. 9 For the diagnosis of KIT-negative GISTs with a wild-type mutation, DOG1 and PKC-y immunostaining will be helpful in solving the diagnostic difficulties. PKC-y was positive in two cases which were completely negative for both KIT and DOG1. Therefore, when a pathologist confronts KIT-negative GIST-like lesions, PKC-y is extremely useful in diagnosing GISTs with certainty. The initial workup for possible GISTs should include KIT and DOG1, and in rare cases, negative for both KIT and DOG1, PKC-y can be used as an important ancillary stain. In summary, we report that a subset of GISTs lack KIT expression, although they show overlapping clinical, histopathological, and molecular features with their KIT-positive counterparts. DOG1 and PKC-y are highly expressed in both KIT-negative and KIT-positive GISTs. Combined immunostaining for DOG1 and PKC-y can be used as an important diagnostic tool in the diagnosis of KIT-negative GISTs, even those that are wild type for KIT and PDGFRA on mutation analysis.
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